NRXP Share Price Performance
US$1.98
0.78 (65.00%)
92.1% undervalued intrinsic discount
US$25.00
Fair Value
Price US$1.98
AnalystLowTarget US$25.00
Fair ValueUS$25.00
Share Pricen/a
NRx Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
NRXP Community Narratives
AN
Fair Value US$25 92.1% undervalued intrinsic discount
Complex Neuroplastic Treatments And Clinic Risks Will Challenge Progress Yet Ultimately Support Long-Term Promise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Complex Neuroplastic Treatments And Clinic Risks Will Challenge Progress Yet Ultimately Support Long-Term Promise
Catalysts About NRx Pharmaceuticals NRx Pharmaceuticals is a clinical stage biopharmaceutical company developing neuroplasticity driven drugs and integrated clinic based treatments for severe mood and brain disorders. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$25
92.1% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
1.39k% p.a.
Profit Margin
14.2%
Future PE
9.23x
Price in 2028
US$17.06
Trending Discussion
Recently Updated Narratives
AN
Complex Neuroplastic Treatments And Clinic Risks Will Challenge Progress Yet Ultimately Support Long-Term Promise
Fair Value: US$25 92.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NRx Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.35
- 59.92%
- -15,727.27%
- -38.5%
About NRXP
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
